-
-
Call more information
660-596-2224 -
Published in Anesth Analg. 2014 Jul;119(1):203-6 Authors: Zhou QHt et al BACKGROUND: The spread of spinal anesthesia is highly unpredictable. In patients with increased abdominal girth and short stature, a greater cephalad spread after a fixed amount of subarachnoidally administered plain bupivacaine is often observed. We hypothesized that there is a strong correlation between abdominal […]
Read MorePublished in Anesth Analg. 2014 Jun;118(6):1326-35 Authors: Nicol AL et al BACKGROUND: Myofascial pain syndrome is a regional condition of muscle pain and stiffness and is classically characterized by the presence of trigger points in affected musculature. Botulinum toxin type A (BoNT-A) has been shown to have antinociceptive properties and elicit sustained muscle relaxation, thereby […]
Read MoreThe U.S. Department of Health and Human Services’ use of the Fraud Prevention System (FPS) led to $54.2 million in actual and projected savings for the Medicare fee-for-service program. However, the Office of Inspector General called for modifications to the FPS to increase savings over time, according to a report it released. Under the Small […]
Read MoreAuthors: Lad S et al Published in Spine 39 (12), E719-27 (May 2014) STUDY DESIGN Retrospective analysis of a population-based insurance claims data set. OBJECTIVE To evaluate the use of spinal cord stimulation (SCS) and lumbar reoperation for the treatment of failed back surgery syndrome (FBSS), and examine their associated complications and health care costs. […]
Read MoreAuthors: Rice ASC et al., Lancet 2014 May 10; 383:1637 A phase 2 trial demonstrates the potential of angiotensin II type 2 antagonists, a new treatment target, to relieve the chronic neuropathic pain of postherpetic neuralgia. Because existing treatments for postherpetic neuralgia are often insufficient or ineffective, researchers have been investigating EMA401, an oral angiotensin […]
Read More